The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boykins, R. A.
Right arrow Articles by Dhawan, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boykins, R. A.
Right arrow Articles by Dhawan, S.
The Journal of Immunology, 1999, 163: 15-20.
Copyright © 1999 by The American Association of Immunologists

CUTTING EDGE

Cutting Edge: A Short Polypeptide Domain of HIV-1-Tat Protein Mediates Pathogenesis

Robert A. Boykins*, Renaud Mahieux{ddagger}, Uma T. Shankavaram§, Yong Song Gho, Sherwin F. Lee{dagger}, Indira K. Hewlett{dagger}, Larry M. Wahl§, Hynda K. Kleinman, John N. Brady{ddagger}, Kenneth M. Yamada and Subhash Dhawan1,{dagger}

* Laboratory of Parasitic Biology and Biochemistry and {dagger} Immunopathogenesis Section, Laboratory of Molecular Virology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892; {ddagger} Laboratory of Receptor Biology and Gene Expression, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892; and § Immunopathology Section and Craniofacial Developmental Biology and Regeneration Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results and Discussion
 References
 
HIV-1 encodes the transactivating protein Tat, which is essential for virus replication and progression of HIV disease. However, Tat has multiple domains, and consequently the molecular mechanisms by which it acts remain unclear. In this report, we provide evidence that cellular activation by Tat involves a short core domain, Tat21–40, containing only 20 aa including seven cysteine residues highly conserved in most HIV-1 subtypes. Effective induction by Tat21–40 of both NF-{kappa}B-mediated HIV replication and TAR-dependent transactivation of HIV-long terminal repeat indicates that this short sequence is sufficient to promote HIV infection. Moreover, Tat21–40 possesses potent angiogenic activity, further underscoring its role in HIV pathogenesis. These data provide the first demonstration that a 20-residue core domain sequence of Tat is sufficient to transactivate, induce HIV replication, and trigger angiogenesis. This short peptide sequence provides a potential novel therapeutic target for disrupting the functions of Tat and inhibiting progression of HIV disease.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results and Discussion
 References
 
The transactivator Tat of HIV-1 (1) is an 86-aa protein released by infected cells and plays a critical role in the progression of HIV disease (1, 2). Transactivation of the HIV-long terminal repeat (LTR)2 promotor by the Tat protein is essential for both viral gene expression and virus replication. Extracellular Tat released by infected cells during the acute phase of infection enters noninfected cells and disrupts many host immune functions by activating a wide variety of genes regulated by specific viral and endogeneous cellular promotors (3, 4). We and others have previously shown that Tat mimics many of the effects of HIV infection of monocytes including increased matrix metalloproteinase-9 and cytokine production, and collagen expression in glioblastoma cells (5, 6, 7). These observations correlate with high levels of cytokines such as IL-1, IL-6, and TNF found in sera from HIV-infected individuals that leads to an increase of the level of HIV replication. These reports suggest a role of extracellular Tat in promoting viral patogenesis. However, Tat has multiple domains, and consequently how Tat induces these diverse effects is not clearly understood. In the present study, we have dissected the sequence of Tat and identified a domain that mediates the cellular and viral effects of extracellular Tat protein. These findings are potentially important for understanding the progression of HIV pathogenesis and in the development of potential therapeutic applications.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results and Discussion
 References
 
Tat protein

The HIV-1-Tat protein used in these experiments was obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, National Institute of Allergies and Infectious Disease, National Institutes of Health, from Dr. Andrew Rice or Dr. John N. Brady (6). HIV-Tat was dissolved at 10 µg/ml in treatment buffer (PBS containing 1 mg/ml BSA and 0.1 mM DTT) and frozen in aliquots at -80°C. Tat preparations were screened and found to be negative for endotoxin contamination.

Synthesis and purification of Tat peptides

Tat peptides were synthesized by solid phase synthesis on an Applied Biosystems peptide synthesizer Model 430A (Foster City, CA) (8). After an initial HPLC purification of the crude cysteine-containing peptides, they were redissolved in 0.1 M Tris acetate buffer (pH 8.3) and air-oxidized overnight. Peptides were then subjected to desalting and purification by reverse-phase HPLC, lyophilized, and stored at -70°C. Peptide identities were confirmed by amino acid compositional analysis and plasma desorption mass spectroscopic analysis.

Monocyte isolation and infection with HIV

Monocytes were isolated from the PBMC of donors seronegative for HIV and hepatitis after leukapheresis and purification by countercurrent centrifugal elutriation (9). Primary monocytes cultured for 5 days were exposed to HIV-1Ba-L, a monocytotrophic HIV strain (Advanced Biotechnologies, Columbia, MD), at a multiplicity of infection of 0.01 infectious virus particles/target cell (10).

Electroporation of cells

Cells were electroporated as previously described (11). CEM cells (12D7) were cultured at a density of 0.5–0.8 x 106 cells/ml with daily media additions. Typically, 5 x 106 cells were electroporated with 5 µg of either purified plasmid or Tat protein and 5 µg of reporter plasmid. Tat peptides or Tat protein and the reporter HIV LTR-chloramphenicol acetyltransferase (CAT) or the TAR mutant HIV TM26 LTR-CAT were mixed with cells and electroporated using a cell porater apparatus (Life Technologies/BRL, Gaithersburg, MD). Cell mixtures were electroporated at 800 µF and 240 V in RPMI 1640 medium without serum. Following electroporation, cells were plated in 10 ml complete medium, and samples were collected 24 h later for CAT assays.

EMSA for NF-{kappa}B

Monocytes (1 x 107/ml) were treated with rTat protein or Tat peptides at 37°C for 15 min. Nuclear extracts were then prepared and analyzed by EMSA as previously described (12).

CAM assay

The chick CAM assay was conducted as described (13) to determine the angiogenic activity of rTat and its derived peptides. Briefly, salt-free aqueous solution (5 µl) containing 5.3 pmol of rTat or its derived peptides (Tat21–40, Tat53–68, or Tat41–52) was loaded onto a 1/4 piece of 15-mm Thermonox disk (Nunc, Naperville, IL), and the sample was dried under sterile air. The disk loaded with sample was placed on the CAM of a 10-day-old chick embryo. After 72 h incubation, negative or positive responses were scored under a microscope. A positive response was characterized as the appearance of a typical radiating network (spokewheel) pattern of new blood vessels around the loaded samples. Assays for each test sample were conducted in two sets of eggs, and each set contained 12–15 eggs.


   Results and Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
References
 
To identify Tat-specific sequences responsible for cellular dysfunction, we synthesized overlapping peptides from various domains of consensus-B and other HIV-1 subtypes (Fig. 1Go). Using these peptides, we have identified a novel domain that can mediate viral transactivation. We found that, like rTat, the 20-aa core domain Tat21–40 containing seven cysteine residues, all of which are strongly conserved in various subtypes, enhanced HIV replication by greater than 4-fold (Table IGo). A peptide derived from the basic domain (Tat53–68) induced a lesser increase in viral replication compared with Tat21–40. In contrast, Tat41–52, a peptide sequence located between the core and the basic domains, and a variety of peptides from other positions in the Tat sequence, had no significant effect on HIV replication.



View larger version (35K):
[in this window]
[in a new window]
  		FIGURE 1. Amino acid sequence of HIV-Tat protein from various subtypes, designated consensus-B, consensus-C, etc. A series of overlapping peptides were synthesized as indicated by lines and residue numbers. Highly conserved residues are indicated at the bottom, with completely conserved residues in consensus-B, -C, -D, -F, -O, and -U subtypes marked by shaded boxes, and residues for which there was only one alternative amino acid are indicated by underlines.

 

View this table:
[in this window]
[in a new window]
  		Table I. Effect of various Tat peptides on HIV replication in monocytes1

 
Consistent with its enhancement of viral replication, Tat21–40 treatment produced a marked increase in HIV-associated cytopathic effects in monocytes as indicated by formation of multinucleated giant cells (Fig. 2Goc); the effects were similar to those induced by rTat protein itself (Fig. 2Gob). The effect of Tat53–68 was substantially less than that of Tat21–40 (Fig. 2God). Tat41–52, the peptide between core and basic domains, and peptides from other Tat domains did not alter HIV-associated cytopathic effects (Fig. 2Goe, and data not shown). Thus, a major active site for stimulating HIV replication and monocyte dysfunction can be localized to the 20-residue peptide Tat21–40.



View larger version (95K):
[in this window]
[in a new window]
  		FIGURE 2. Effect of rTat and Tat peptides on HIV-associated cytopathic effects in monocytes. At day 5 postinoculation, cells were washed once with PBS, fixed, and Wright-stained. HIV-associated cytopathic effects were determined by examining for the formation of multinucleated giant cells. a, HIV-infected monocytes. b–e, Monocytes infected in the presence rTat (b), Tat21–40 (c), Tat53–68 (d), and Tat41–52 (e). Morphology of uninfected monocytes is shown in f.

 
One of the mechanisms by which HIV-Tat potentiates HIV replication involves transactivation of the HIV-1 LTR via its binding to the TAR sequence along with other cellular factors, resulting in increased viral transcription initiation and elongation (14). To characterize further the mechanism of Tat transactivation of the HIV-LTR, CEM lymphoid cells were transfected with wild-type promoter in the presence of various Tat peptides, and the extent of transactivation was determined using CAT assays (14). These analyses revealed a 9-fold induction of HIV-LTR by the Tat21–40 peptide (Fig. 3Go, A and B); full-length rTat produced a 25-fold induction. The actual effectiveness of induction by Tat21–40 might be greater than observed due to the low solubility of this complex hydrophobic peptide in aqueous buffers.



View larger version (38K):
[in this window]
[in a new window]
  		FIGURE 3. Transactivation of HIV-LTR by rTat and Tat peptides by CAT assay. A, Transfection of CEM cells with wild-type HIV-LTR Tat construct. B, Quantitative analysis of HIV-LTR transactivation by Tat and Tat peptides. C, Transfection of CEM cells with a TAR mutant construct as a control in the presence of the indicated peptides.

 
We found that the presence of Cys22 in core domain Tat21–40 (and three adjacent residues) was critical for viral activation, because deletion of these residues substantially reduced the ability of Tat21–40 to activate HIV infection (Tat25–40 in Fig. 3Go and Table IGo). Because rTat activation of the HIV-LTR promoter is required for productive HIV replication (15), our demonstration of induction by the Tat21–40 sequence conserved in most HIV-1 subtypes further confirms a functional role of Tat21–40 in HIV infection. In contrast, transfection of CEM cells with a TAR mutant (HIV TM26 LTR-CAT) construct in the presence of the same peptides failed to induce HIV-LTR activation (Fig. 3GoC), confirming that the HIV-LTR activation by Tat peptides was TAR-specific. Previous studies have demonstrated that the arginine-rich basic domain located between residues 49 and 57 constitutes the TAR-binding activity (16, 17, 18, 19). Mutation or deletion of the basic domain severely diminishes the ability of Tat to transactivate the LTR. The overlapping peptide(s) from this region tested in the present study were not as active as Tat21–40 peptide. Studies are underway to investigate the ability of the Tat21–40 peptide to induce TAR-dependent transcription.

Although the precise mechanism of virus regulation by host factors is not clear, it is generally believed that in addition to other unknown factors, Tat and cytokines play a key role in the pathogenesis of HIV infection. Extracellular HIV-Tat causes activation of intracellular signal transduction pathways that culminate in the production of various cytokines (5, 20). Therefore, because of its ability to induce host factors, Tat is believed to be a key factor for viral enhancement. HIV-Tat activates both viral and host cell genes, and the host NF-{kappa}B transcription factor contributes to immune dysregulation during HIV infection (21, 22). Because macrophages are a well-known reservoir for HIV in vivo, we examined the ability of Tat peptides to activate the expression of NF-{kappa}B in these cells. Monocytes were treated with rTat and other peptides, nuclear extracts were prepared, and NF-{kappa}B activity was examined by gel shift assay using an NF-{kappa}B consensus oligonucleotide. Our results show that the ability of HIV-Tat to activate NF-{kappa}B was retained in core peptide Tat21–40 and to a lesser extent Tat53–68 (Fig. 4Go). Treatment of monocytes with the Tat21–40 peptide rapidly activated NF-{kappa}B (within 15 min after exposure) by greater than 9-fold as compared with 3-fold induction by Tat53–68. Interestingly, despite inducing NF-{kappa}B activity, Tat53–68 had little effect on transactivation of HIV-LTR as shown in Fig. 3Go. These observations delineate two distinct mechanisms for viral activation by HIV-Tat: 1) TAR-dependent transactivation of HIV-LTR involving Tat21–40 domain, and 2) TAR-independent activation of virus replication involving the host factor NF-{kappa}B by an intracellular signal transduction pathway. Our results are complementary to those recently reported by Mayne et al. (23), who have demonstrated the involvement of protein kinase A, phospholipase C and protein tyrosine kinase in Tat-mediated induction of NF-{kappa}B and cytokine production by monocytes.



View larger version (51K):
[in this window]
[in a new window]
  		FIGURE 4. Effect of Tat or Tat peptides on activation of NF-{kappa}B in monocytes. Monocytes were treated with Tat or Tat peptides at 37°C for 15 min. Nuclear extracts were then prepared, and NF-{kappa}B activity was assessed by gel-shift assay.

 
Tat is released by HIV-infected cells into the extracellular milieu, and has been implicated as a cofactor in the pathogenesis of Kaposi’s sarcoma (24), an angioproliferative disease frequently seen in HIV-infected individuals. There is increasing evidence that HIV-Tat induces endothelial cell migration, invasion, and angiogenic processes in vivo (25). To test for potential angiogenic activity of the core domain implicated above in viral pathogenesis, we examined the ability of Tat peptides to induce neovascularization using the CAM assay. Our results indicate that picomol quantities (5.2 pmol/egg) of Tat21–40 can induce neovascularization (Fig. 5Go). Recombinant Tat alone was less effective in inducing an angiogenic response, as reported by others (25). No significant angiogenic response was observed using vehicle alone or the control peptide Tat41–52 containing sequence between the core and basic domains (Fig. 5Go). Interestingly, Tat53–68 from the Tat basic domain also had substantial activity; as noted above, this peptide had either partial or minimal activities in assays for HIV replication, cytopathic effects, and transactivation of the HIV-LTR promotor. The exact mechanism of neovascularization in vivo is not clear. However, one scenario is that Tat-induced cytokines stimulate endothelial cells, degrade basement membrane matrix by local enhancement of matrix metalloproteinase-9 secretion and migrate into adjacent tissue to form new blood vessel networks.



View larger version (59K):
[in this window]
[in a new window]
  		FIGURE 5. Induction of angiogenesis by rTat or Tat-derived peptides in the chick CAM assay. A, rTat or its derived peptides (Tat21–40, Tat53–68, or Tat41–52) was loaded (5.3 pmol/egg) on CAMs of 10-day-old embryos. After 72 h incubation at 37°C, fat emulsion (whipping cream) was injected under the CAMs to help visualize the vascular networks. Disks and surrounding CAMs were photographed: vehicle (a), rTat (b), Tat21–40 (c), Tat53–68 (d), or Tat41–52 (e). B, Incidence of angiogenic response induced by rTat or Tat peptides. Each bar represents the average percentage of positive eggs from two independent sets of assays consisting of 12–15 eggs. Positive responses involved eggs which showed a spokewheel pattern of new blood vessels around the loaded samples. p values were calculated by using the Student’s paired t test, based on comparisons with water control samples tested at the same time, *, p < 0.02. p values vs control were as follows: rTat, 0.104; Tat21–40, 0.006; Tat53–68, 0.017; and Tat41–52, 0.313.

 
Detectable levels of Tat have been reported in HIV-infected individuals (26), suggesting the presence of extracellular HIV-Tat protein in certain phases of HIV infection. It has also been shown that high levels of anti-Tat Abs are directly related to low viral load (27, 28) in seropositive nonprogressor patients. Therefore, a strategy targeting a required site(s) in Tat might provide a novel therapeutic modality to reduce disease progression in HIV-infected individuals. In this paper we have provided evidence that a short core domain of the Tat protein, Tat21–40 consisting of 7 cysteine residues and only 13 other amino acids, is a potent inducer of HIV transactivation and replication. This domain is highly conserved in various HIV-1 subtypes, including the newly discovered group 0. Our results suggest that the mechanism by which HIV-Tat activates cellular functions involves primarily the Tat21–40 core domain, with possible lesser contributions from the Tat53–68 domain. Some of these results are complementary to those demonstrating the involvement of Tat and the core domain in the process of monocyte chemotaxis in response to Tat (29, 30), which may contribute to altered immunoregulation in HIV-infected individuals. It is important to note that monocytes differentiate into tissue-resident macrophages, which are nonrecirculating cells. Therefore, HIV-infected macrophages could continue to infect neighboring normal cells and contribute to the tissue damage typically seen after HIV infection. Thus, the active domain Tat21–40, possibly in combination with Tat53–68, provides a novel candidate target for a potential therapeutic vaccine or a dominant-negative strategy to reduce Tat-mediated progression of disease in individuals with HIV infection.


   Acknowledgments
 
We thank Dr. Hira Nakhasi for constant support, suggestions, and critical review of the manuscript.


   Footnotes
 
1 Address correspondence and reprint requests to Dr. Subhash Dhawan, Immunopathogenesis Section, Laboratory of Molecular Virology, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike (HFM-315), Rockville, MD 20852. E-mail address: Back

2 Abbreviations used in this paper: LTR, long terminal repeat; CAM, chorioallantoic membrane; CAT, chloramphenicol acetyltransferase. Back

Received for publication March 12, 1999. Accepted for publication April 30, 1999.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
 References
 

  1. Jeang, K. T.. 1998. Tat, Tat-associated kinase, and transcription. J. Biomed. Sci. 5:24.[Medline]
  2. Ensoli, B., L. Buonaguru, G. Barillari, V. Fiorelli, R. Gendelman, R. A. Morgan, P. Wingfield, R. C. Gallo. 1993. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J. Virol. 67:277.[Abstract/Free Full Text]
  3. Vaishnav, Y. N., and F. Wong-Staal, F. 1991. The biochemistry of AIDS. Annu. Rev. Biochem. 60:577.
  4. Kumar, A., S. K. Manna, S. Dhawan, B. B. Aggarwal. 1998. HIV-Tat protein activates c-Jun N-terminal kinase and activator protein-1. J. Immunol. 161:776.[Abstract/Free Full Text]
  5. Lafrenie, R. M., L. M. Wahl, J. S. Epstein, K. M. Yamada, S. Dhawan. 1997. Activation of monocytes by HIV-Tat treatment is mediated by cytokine expression. J. Immunol. 159:4077.[Abstract]
  6. Lafrenie, R. M., L. M. Wahl, J. S. Epstein, I. K. Hewlett, K. M. Yamada, S. Dhawan. 1996. HIV-1-Tat modulates the function of monocytes and alters their interactions with human microvessel endothelial cells. J. Immunol. 156:1638.[Abstract]
  7. Taylar, J. P., C. Cupp, A. Diaz, M. Choudhury, K. Khalili, S. A. Jimenez, S. Amini. 1992. Activation of expression of genes for extracellular matrix proteins in Tat-producing glioblastoma cells. Proc. Natl. Acad. Sci. USA 89:9617.[Abstract/Free Full Text]
  8. Merrifield, R. B.. 1963. Solid-phase peptide synthesis: the synthesis of a tetrapeptide. J. Am. Chem. Soc. 85:2149.
  9. Wahl, L. M., and P. D. Smith. 1991. Isolation of monocyte/macrophage populations. In Current Protocols in Immunology. J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober, eds. John Wiley & Sons, New York, Vol. 2, p. 7.6.1.
  10. Dhawan, S., B. S. Weeks, C. Soderland, H. W. Schnaper, L. A. Toro, S. P. Asthana, I. K. Hewlett, W. G. Stetler-Stevenson, S. S. Yamada, K. M. Yamada, M. S. Meltzer. 1995. HIV-1 infection alters monocyte interaction with human microvascular endothelial cells. J. Immunol. 154:422.[Abstract]
  11. Kashanchi, F., M. R. Sadaie, J. N. Brady. 1997. Inhibition of HIV-1 transcription and virus replication using soluble Tat peptide analogs. Virology 227:431.[Medline]
  12. Dhawan, S., S. Singh, B. B. Aggarwal. 1997. Induction of endothelial cell surface adhesion molecules by tumor necrosis factor is blocked by protein tyrosine phosphatase inhibitors: role of the nuclear factor NF-{kappa}B. Eur. J. Immunol. 27:2172.[Medline]
  13. Gho, Y. S., C.-B. Chae. 1997. Anti-angiogenin activity of the peptides complementary to the receptor-binding site of angiogenin. J. Biol. Chem. 272:24294.[Abstract/Free Full Text]
  14. Cujec, T. P., H. Cho, E. Maldonado, J. Meyer, D. Reinberg, B. M. Peterlin. 1997. The human immunodeficiency virus transactivator Tat interacts with the RNA polymerase II holoenzyme. Mol. Cell. Biol. 17:1817.[Abstract]
  15. Yankulov, K., D. Bentley. 1998. Transcriptional control: Tat cofactors and transcriptional elongation. Curr. Biol. 18:R447.
  16. Garcia, J. A., D. Harrich, E. Soultanakis, F. Wu, R. Mitsuyasu, R. B. Gaynor. 1989. Human immunodeficiency virus type 1 LTR TATA and TAR region sequences required for transcriptional regulation. EMBO J. 8:765.[Medline]
  17. Weeks, K. M., C. Ampe, S. C. Schultz, T. A. Steitz, D. M. Crothers. 1990. Fragments of the HIV-1 Tat protein specifically bind TAR RNA. Science 249:1281.[Abstract/Free Full Text]
  18. Cordingley, M. G., R. L. Lafemina, P. L. Callahan, J. H. Condra, V. V. Sardana, D. J. Graham, T. M. Nguyen, K. L. LeGrow, L. Gotlib, A. J. Schlabach, R. J. Colonno. 1990. Sequence-specific interaction of Tat protein and Tat peptides with the transactivation-responsive sequence element of human immunodeficiency virus type 1 in vitro. Proc. Natl. Acad. Sci. USA 87:8985.[Abstract/Free Full Text]
  19. Feng, S., E. C. Holland. 1988. HIV-1 tat trans-activation requires the loop sequence within tar. Nature 334:165.[Medline]
  20. Chen, P., M. Mayne, C. Power, A. Nath. 1997. The Tat protein of HIV-1 induces tumor necrosis factor-{alpha} production: implications for HIV-1-associated neurological diseases. J. Biol. Chem. 272:22385.[Abstract/Free Full Text]
  21. Conant, K., M. Ma, A. Nath, E. O. Major. 1996. Extracellular human immunodeficiency virus type 1 Tat protein is associated with an increase in both NF-{kappa}B binding and protein kinase C activity in primary human astrocytes. J Virol. 70:1384.[Abstract]
  22. Ott, M., J. C. Lovett, L. Mueller, E. Verdin. 1998. Superinduction of IL-8 in T cells by HIV-1 Tat protein is mediated through NF-{kappa}B factors. J. Immunol. 160:2872.[Abstract/Free Full Text]
  23. Mayne, M., A. C. Bratanich, P. Chen, F. Rana, A. Nath, C. Power. 1998. HIV- 1 Tat molecular diversity and induction of TNF-{alpha}: implications for HIV-induced neurological disease. Neuroimmunomodulation 5:184.[Medline]
  24. Albini, A., G. Barillari, R. Benelli, R. C. Gallo, B. Ensoli. 1995. Angiogenic properties of human immunodeficiency virus type 1 Tat protein. Proc. Natl. Acad. Sci. USA 92:4838.[Abstract/Free Full Text]
  25. Albini, A., R. Benelli, M. Presta, M. Rusnati, M. Ziche, A. A. Rubartelli, G. Paglialunga, F. Bussolino, D. Noonan. 1996. HIV-Tat protein is heparin-binding angiogenic growth factor. Oncogene 12:289.[Medline]
  26. Westendorp, M. O., R. Frank, C. Ochsenbauer, K. Stricker, J. Dhein, H. Walczak, K. M. Debatin, P. H. Krammer. 1995. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature 375:497.[Medline]
  27. Re, M. C., G. Furlini, G. M. Vignoli, E. Ramazzotti, G. Zauli, M. La Placa. 1996. Antibody against human immunodeficiency virus type 1 (HIV-1) Tat protein may have influenced the progression of AIDS in HIV-1-infected hemophiliac patients. Clin. Diagn. Lab. Immunol. 3:230.[Abstract]
  28. Poznansky, M. C., R. Foxall, A. Mhashilkar, R. Coker, S. Jones, U. Ramstedt, W. Marasco. 1998. Inhibition of human immunodeficiency virus replication and growth advantage of CD4+ T cells from HIV-infected individuals that express intracellular antibodies against HIV-1 gp120 or Tat. Hum. Gene Ther. 9:487.[Medline]
  29. Lafrenie, R. M., L. M. Wahl, J. S. Epstein, I. K. Hewlett, K. M. Yamada, S. Dhawan. 1996. HIV-Tat protein promotes chemotaxis and invasive behavior by monocytes. J. Immunol. 157:974.[Abstract]
  30. Albini, A., R. Benelli, D. Giunciuglio, T. Cai, G. Mariani, S. Ferrini, D. M. Noonan. 1998. Identification of a novel domain of HIV Tat involved in monocyte chemotaxis. J. Biol. Chem. 273:15895.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Leukoc. Biol.Home page
U. Mahlknecht, I. Dichamp, A. Varin, C. Van Lint, and G. Herbein
NF-{kappa}B-dependent control of HIV-1 transcription by the second coding exon of Tat in T cells
J. Leukoc. Biol., March 1, 2008; 83(3): 718 - 727.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Kittiworakarn, A. Lecoq, G. Moine, R. Thai, E. Lajeunesse, P. Drevet, C. Vidaud, A. Menez, and M. Leonetti
HIV-1 Tat Raises an Adjuvant-free Humoral Immune Response Controlled by Its Core Region and Its Ability to Form Cysteine-mediated Oligomers
J. Biol. Chem., February 10, 2006; 281(6): 3105 - 3115.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
W. A. Burgers, J. H. van Harmelen, E. Shephard, C. Adams, T. Mgwebi, W. Bourn, T. Hanke, A.-L. Williamson, and C. Williamson
Design and preclinical evaluation of a multigene human immunodeficiency virus type 1 subtype C DNA vaccine for clinical trial
J. Gen. Virol., February 1, 2006; 87(2): 399 - 410.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
S. M. Reza, L.-M. Shen, R. Mukhopadhyay, M. Rosetti, T. Pe'ery, and M. B. Mathews
A Naturally Occurring Substitution in Human Immunodeficiency Virus Tat Increases Expression of the Viral Genome
J. Virol., August 1, 2003; 77(15): 8602 - 8606.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
Y. Yang, I. Tikhonov, T. J. Ruckwardt, M. Djavani, J. C. Zapata, C. D. Pauza, and M. S. Salvato
Monocytes Treated with Human Immunodeficiency Virus Tat Kill Uninfected CD4+ Cells by a Tumor Necrosis Factor-Related Apoptosis-Induced Ligand-Mediated Mechanism
J. Virol., June 15, 2003; 77(12): 6700 - 6708.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
O. Rohr, D. Lecestre, S. Chasserot-Golaz, C. Marban, D. Avram, D. Aunis, M. Leid, and E. Schaeffer
Recruitment of Tat to Heterochromatin Protein HP1 via Interaction with CTIP2 Inhibits Human Immunodeficiency Virus Type 1 Replication in Microglial Cells
J. Virol., May 1, 2003; 77(9): 5415 - 5427.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
I. Tikhonov, T. J. Ruckwardt, G. S. Hatfield, and C. D. Pauza
Tat-Neutralizing Antibodies in Vaccinated Macaques
J. Virol., March 1, 2003; 77(5): 3157 - 3166.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Yang, B. Dong, P. R. Mittelstadt, H. Xiao, and J. D. Ashwell
HIV Tat Binds Egr Proteins and Enhances Egr-dependent Transactivation of the Fas Ligand Promoter
J. Biol. Chem., May 24, 2002; 277(22): 19482 - 19487.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
G. Barillari and B. Ensoli
Angiogenic Effects of Extracellular Human Immunodeficiency Virus Type 1 Tat Protein and Its Role in the Pathogenesis of AIDS-Associated Kaposi's Sarcoma
Clin. Microbiol. Rev., April 1, 2002; 15(2): 310 - 326.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
Z. Gao, J. Golob, V. M. Tanavde, C. I. Civin, R. G. Hawley, and L. Cheng
High Levels of Transgene Expression Following Transduction of Long-Term NOD/SCID-Repopulating Human Cells with a Modified Lentiviral Vector
Stem Cells, May 1, 2001; 19(3): 247 - 259.
[Abstract] [Full Text]

Home page
 J. Virol.Home page
Y. Guan, J. B. Whitney, C. Liang, and M. A. Wainberg
Novel, Live Attenuated Simian Immunodeficiency Virus Constructs Containing Major Deletions in Leader RNA Sequences
J. Virol., March 15, 2001; 75(6): 2776 - 2785.
[Abstract] [Full Text]

Home page
 Proc. Natl. Acad. Sci. USAHome page
P. Secchiero, D. Zella, S. Curreli, P. Mirandola, S. Capitani, R. C. Gallo, and G. Zauli
Pivotal role of cyclic nucleoside phosphodiesterase 4 in Tat-mediated CD4+ T cell hyperactivation and HIV type 1 replication
PNAS, December 8, 2000; (2000) 11512398.
[Abstract] [Full Text]

Home page
 Proc. Natl. Acad. Sci. USAHome page
P. Secchiero, D. Zella, S. Curreli, P. Mirandola, S. Capitani, R. C. Gallo, and G. Zauli
Pivotal role of cyclic nucleoside phosphodiesterase 4 in Tat-mediated CD4+ T cell hyperactivation and HIV type 1 replication
PNAS, December 19, 2000; 97(26): 14620 - 14625.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boykins, R. A.
Right arrow Articles by Dhawan, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boykins, R. A.
Right arrow Articles by Dhawan, S.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS